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Outdated and inadequate disease 
prevalence data
First and foremost, reliable and representative data on the 
prevalence and distribution patterns of inherited dis-
orders are currently lacking at global, regional, country 
and community levels, and phenotypic heterogeneity in 
more rare disorders often goes undocumented. An 
innovative and determined attempt to fill this void was 
made in the 2006 March of Dimes Global Report on Birth 
Defects, based on the summary statistic that 6% of 
children (7.9 million) are born annually with a serious 
birth defect of genetic or partially genetic origin, 90% of 
whom are resident in low or middle income countries 
(LMIC).
5 However the report was critically dependent on 
the available literature, and by providing annual disease 
estimates precise to a single integer, e.g. with glucose 
6-phosphate dehydrogenase deficiency estimated in 
177,032 births worldwide, it conveyed a questionable 
sense of security in the accuracy and completeness of the 
data collected. 
There has also been a failure to acknowledge that in 
many LMIC the population is sub-divided into multiple 
ethnic, religious, language and social groups within which 
individuals live, marry and reproduce. The net result is 
that co-resident communities commonly exhibit 
markedly different inherited disease profiles and 
prevalences. For example, in India a widely cited estimate 
is that 3–4% of the population are carriers of 
β-thalassaemia,
6 with five mutations IVSI-5 (G>C), IVSI-1 
(G>T), 619-bp del, Codon 41/42 (-TCTT) and Codon 
8/9 (+G), accounting for 90% of all cases. However, these 
data were very largely based on the populations of just 
three of the 35 states and Union territories of India, 
Gujarat, Punjab and Maharashtra, with significantly 
different β-thalassaemia mutation profiles observed in 
other regions of the country.
7 Further, and perhaps of 
greater significance from a genetic epidemiology 
perspective, carrier rates for β-thalassaemia ranged 
from 0% to 9.3% in different ethnic groups.
8 Which raises 
a major query as to the practical value of a national 
disease prevalence estimate in a genetically and socially 
heterogeneous country of approximately 1.3 billion 
people and comprising over 50,000 endogamous 
communities. The issue of population stratification is 
not restricted to large countries such as India with, for 
example, significant genetic sub-divisions clearly 
identified in Iceland with a population of just 320,000.
9 
prOblems engendered by inadequate 
health data
Difficulties that can arise because of the paucity of 
reliable prevalence data on genetic disorders influenced 
The Global Burden of Disease Study 2010 (GBD 2010),
10 
launched in The Royal Society, London in 2012, with the 
findings presented in The Lancet.
11 The 291 major 
diseases and injuries examined were collated into 67 
groups of risk factors and hundreds of sub-categories. 
The specific genetic disorders included in GBD 2010 
were haemoglobinopathies and haemolytic anaemias, 
which were listed in the sub-category ‘diabetes, urogenital, 
blood, and endocrine diseases’, and congenital anomalies, 
listed under ‘other non-communicable diseases’. It is 
therefore no great surprise that in comparison with the 
five leading risk factors identified as causing poor health: 
high blood pressure, tobacco use (excluding second-
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solid fuels, and a diet low in fruits, genetic disorders did 
not feature prominently in terms of the overall global 
health burden, or in health metrics such as years lived 
with disability (YLDs).
12
Interestingly, the Director General of the World Health 
Organization (WHO) drew attention to the fact that in 
a number of areas the results of GBD 2010 differed 
substantially from analyses by WHO and other United 
Nations entities, and indicated her intention both to 
improve data on global health and to close data gaps 
which especially impact on the populations of LMIC.
13 To 
some extent these deficiencies may be ameliorated in a 
current WHO initiative: Grand Challenges in Genomics for 
Public Health in Developing Countries,
14 with the findings 
and ranked recommendations scheduled for presentation 
in 2013. But once again the data on which the 
recommendations of expert panel members are based will 
be seriously incomplete, necessitating reliance on statistical 
inferences being drawn from data sets of approximate 
comparability.   And in most LMIC it is the least advantaged 
sections of the population who will continue to be 
significantly under-represented in disease statistics.
The recent re-ordering of research priorities towards 
studies based on rare diseases may assist in focusing 
more appropriate attention on genetic disorders.  Within 
Europe rare diseases are defined as disorders that 
individually affect fewer than 5/10,000 people. But 
according to EUROCAT, the organisation responsible 
for the surveillance of congenital anomalies in Europe,
15 
collectively they account for a significant proportion of 
the overall burden of disease, with some 6–8% of the 
European Union (EU) population expressing one or 
more of 5,000 to 8,000 rare diseases, i.e. between 27 
and 36 million people. Detailed information on these 
rare diseases is listed on the Orphanet portal.
16 
It will be some time before equivalently representative 
data are available for most LMIC. However, the recently 
funded EU Framework 7 programme RD-Connect, with 
25 EU, North American and Australian collaborating 
centres, may help to close this gap (http://rd-connect.eu). 
RD-Connect is planned as an integrated platform 
connecting patient registries, biobanks and clinical 
bioinformatics for research into rare diseases. The 
practical importance of disease registries in a LMIC has 
been demonstrated for β-thalassaemia in India, where 
the registry ThalInd is a nationally available resource, 
with internet access permitting secure data entry even 
for subjects resident in rural and remote regions and 
improved patient management by local health 
practitioners.
17 More generally, a customisable modular 
disease registry framework that offers secure multi-level 
access and interoperability with other data systems has 
been designed for a range of rare diseases.
18
addressing the shOrtage Of trained 
persOnnel and facilities
Lack of formal training in genetics for clinicians and 
other healthcare professionals in LMIC has led to 
ongoing problems with diagnosis and in patient care.  This 
shortcoming exists even in richer regions, such as the 
Middle East, and to date attempts to effect significant 
improvements have met with only limited success.
19   The 
situation is exacerbated by poor public knowledge of 
genetics, and a consequent lack of understanding of how 
or why certain diseases are transmitted within families 
and communities.
20 This difficulty also exists in high 
income countries, an ongoing example being the 
controversy surrounding cousin marriage in the UK 
Pakistani community, which has been affected by ill-
advised public interventions by politicians and others.
20,21
Increased numbers of clinical geneticists are essential to 
facilitate progress, and trained genetic counsellors, genetic 
nurses, and medical laboratory scientists are also needed 
to provide requisite levels of diagnostic skills and patient 
care. The requirement for suitably skilled and experienced 
staff is especially acute in the many countries where major 
population sub-divisions exist, with strict community 
endogamy and very often a traditional preference for 
close kin marriage.
20 Under these circumstances the 
expression of rare or even unique founder mutations 
becomes more probable, and in numerically small 
populations genetic drift also can play a significant role, as 
exemplified by the ‘Finnish disease heritage’.
20
Unfortunately, in many countries the trained personnel 
needed to provide a fully fledged clinical genetics service 
simply may not be available, and/or their appointment is 
not feasible within the scope of the national or local 
budget. The low priority ranking of genetic disorders in 
programmes such as GBD 2010 also may deter 
governments from investing in genetic services, with 
preference given to issues perceived to be of greater 
importance from a public health perspective. Brazil 
exemplifies several of these problems but the country’s 
health planners have also devised various means for 
their partial solution. As an example, the Community 
Health Agents (CHA) Programme was established in 
1991 as part of the national healthcare scheme (Sistema 
Único de Saúde). Community Health Agents have a 
minimum of eight years of education and since they are 
recruited from local communities they are conversant 
with local health issues. Given the small numbers of 
clinical geneticists in Brazil, and in the absence of a formal 
career structure for genetic counsellors, the assistance of 
CHAs has proved to be invaluable in the early identification 
and follow-up of individuals and families with rare 
inherited disorders.
22 At least as a short- to medium-
term measure, the CHA system offers a model that 
could productively be adopted by other LMIC, particularly 
in geographically more remote regions.
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disease registries and natiOnal, 
regiOnal and internatiOnal 
cOllabOratiOns
Registries for specific disorders within the UK have 
enabled areas of high disease prevalence to be identified, 
which is increasingly important given the multi-ethnic 
nature of the population.  As previously noted, EUROCAT 
provides a similar, highly regarded service within the EU 
by collating and analysing data on congenital disorders in 
the approximately 1.7 million births delivered per year. 
Equivalent regional databases for genetic disorders 
include Estudio Colaborativo Latino Americano de 
Malformaciones Congenitas (ECLAMC),
23 established in 
1967 and now covering maternity hospitals in all 12 
countries of South America plus Costa Rica and the 
Dominican Republic, and the Catalogue of Transmission 
Genetics in Arabs, which is maintained by the Centre for 
Arab Genomic Studies (CAGS) and analyses data from 
23 countries in the Middle East and North Africa.
24 Each 
of these regional bodies additionally is a contributing 
member of the WHO Collaborating Centre for the 
Surveillance of Congenital Anomalies.
25
Internet-based communication and mobile telephony 
are substantially easing the difficulties faced in providing 
healthcare and advice to rural and remote communities. 
However, rather than these facilities simply being 
restricted to national or regional populations, they also 
can benefit from North-South collaborations. In 
particular since most clinical geneticists in the UK and 
other western countries now have extensive experience 
in the diagnosis and treatment of patients with non-
European ancestries. An example of this type of 
synergistic North-South cooperation is the recently 
established Action on Birth Defects programme in the 
mainly rural state of Uttarakhand in northern India, 
where inputs from experienced health practitioners 
from other Indian states, the Public Health Genomics 
Foundation in Cambridge, UK and the Centre for 
Comparative Genomics in Murdoch University, 
Australia have been integrated with local expertise to 
formulate a public health strategy for congenital disorders.
tOwards a brave new future
Since the completion of the Human Genome Project a 
decade ago the initially underestimated complexity of 
genetic disease and its impact on human health has 
become increasingly obvious. The role of microRNAs, 
epigenetic control of gene expression, the heterogeneity 
of many inherited diseases, and the as-yet ‘missing’ 
information on the heritability of common complex 
disorders
26 all require solution. For the populations of 
high income countries, personal genome sequencing is 
increasingly accessible as a means of providing differential 
diagnoses of genetic disorders and in identifying 
individualised therapies.
27 The picture is markedly 
different for a large majority of those living in LMIC, with 
inadequate data, a lack of trained personnel, restricted 
diagnostic facilities, and cost constraints retarding 
progress. But even in these countries significant advances 
are being made, and the increasing affordability of 
genomic analysis combined with internet-based 
bioinformatics systems and comprehensive disease 
registries suggest that this process can and will accelerate 
within the present decade, allowing a better life for 
those with genetic disorders and offering renewed hope 
to their families and communities.
references
1  de Ligt J, Willemsen MH, van Bon BW et al. Diagnostic exome 
sequencing in persons with severe intellectual disability. New Engl 
J Med 2012; 367:1921–9. http://dx.doi.org/10.1056/NEJMoa1206524
2  Talkowski ME, Ordulu Z, Pillalamarri V et al. Clinical diagnosis by 
whole-genome sequencing of a prenatal sample. New Engl J Med 
2012; 367:2226–32. http://dx.doi.org/10.1056/NEJMoa1208594
3  Saunders CJ, Miller NA, Soden SE et al. Rapid whole-genome 
sequencing for genetic disease diagnosis in neonatal intensive care 
units. Sci Transl Med 2012; 4:154ra135.
4  Bainbridge MN, Wiszniewski W, Murdock DR et al. Whole-genome 
sequencing for optimized patient management. Sci Transl Med 2011; 
3:87re3.
5  Christianson A, Howson CP, Modell B. March of Dimes global report 
on birth defects [Internet]. White Plains, New York: March of Dimes 
Birth Defects Foundation; 2006 [cited 2013 Jan 17]. Available from: 
http://passthrough.fw-notify.net/download/032457/http://www.
marchofdimes.com/downloads/birth_defects_report-pf.pdf 
6  World Health Organization. Management of haemoglobin disorders 
[Internet]. Geneva: WHO; 2008 [cited 2013 Jan 17]. Available from: 
http://www.who.int/genomics/WHO-TIF_genetics_final.pdf 
7  Sinha S, Black ML, Agarwal S et al. Profiling β-thalassaemia 
mutations in India at state and regional levels: implications for 
genetic education, screening and counselling programmes. Hugo J 
2009; 3:51–62. http://dx.doi.org/10.1007/s11568-010-9132-3 
8  Mohanty D, Colah RB, Gorakshakar AC et al. Prevalence of 
β-thalassemia and other haemoglobinopathies in six cities in India: 
a multicentre study. J Community Genet 2012; 4:33–42. http://dx.doi.
org/10.1007/s12687-012-0114-0
9  Helgason A, Yngvadóttir B, Hrafnkelsson B et al. An Icelandic 
example of the impact of population structure on association 
studies. Nat Genet 2005; 37:90–5. 
10 Institute for Health Metrics and Evaluation. Global burden of 
diseases, injuries, and risk factors study 2010 [Internet]. Seattle, 
Washington; IHME; 2010 [cited 2013 Jan 17]. Available from: http://
www.healthmetricsandevaluation.org/gbd/research/project/global-
burden-diseases-injuries-and-risk-factors-study-2010 
11  Horton R. GBD 2010: understanding disease, injury, and risk. Lancet 
2013; 380:2053–4. http://dx.doi.org/10.1016/S0140-6736(12)62133-3
12  Vos T, Flaxman AD, Naghavi M et al. Years lived with disability 
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: 
a systematic analysis for the GBD Study 2010. Lancet 2013; 
380:2163–96. http://dx.doi.org/10.1016/S0140-6736(12)61729-2
13    Chan M. From new estimates to better data. Lancet 2013; 
380:2054. http://dx.doi.org/10.1016/S0140-6736(12)62135-7
14  World Health Organization. Grand challenges in genomics for public 
health in developing countries [Internet]. Geneva: WHO; 2013 [cited 
2013 Jan 17]. Available from: http://www.who.int/rpc/grand_
challenges.pdf 
J R Coll Physicians Edinb 2013; 43:7–10
© 2013 RCPE
Genetics and global healthcare10
c
l
i
n
i
c
a
l
15  European Surveillance of Congenital Abnormalities (EUROCAT) 
[Internet]. Ulster: EUROCAT [cited 2013 Jan 17]. Available from: 
http://www.eurocat-network.eu/ 
16  Orphanet. The portal for rare diseases and orphan drugs [Internet]. 
Paris: Orphanet [cited 2013 Jan 17]. Available from: http://www.
orpha.net/ 
17  Sinha S, Black ML, Agarwal S et al. ThalInd, a β-thalassemia and 
hemoglobinopathies database for India: defining a model country-
specific and disease-centric bioinformatics resource. Hum Mutat 
2011; 32:887–93. http://dx.doi.org/10.1002/humu.21510
18  Bellgard MI, Macgregor A, Janon F et al. A modular approach to 
disease registry design: successful adoption of an internet-based 
rare disease registry. Hum Mutat 2012; 33:E2356–66. http://dx.doi.
org/10.1002/humu.22154
19  Hamamy H, Bittles AH. Genetic clinics in Arab countries: meeting 
individual, family and community needs. Public Health Genomics 
2009; 12:30–40. http://dx.doi.org/10.1159/000153428
20 Bittles AH. Consanguinity in context. Cambridge: Cambridge 
University Press; 2012. Available from: www.cambridge.
org/9780521781862
21 Qureshi N, Raeburn S. Risks to offspring of consanguineous 
marriage: we need straight, not crooked thinking. J R Coll Physicians 
Edinb 2011; 41:194–5. http://dx.doi.org/10.4997/JRCPE.2011.301
22  Acosta AX, Abé-Sandes K, Giugliani R et al. Delivering genetic 
education and genetic counselling for rare diseases in rural Brazil. J 
Genet Counsel 2013. http://dx.doi.org/10.1007/s10897-013-9570-x 
23  Centro de Educacion Medica e Investigaciones clinicas. ECLAMC 
– Estudio Collaborativo Latinamericano de Malformaciones Congenitas 
[Internet]. Argentina: CEMIC [cited 2013 Jan 17]. Available from: 
www.cemic.edu.ar/investigacion/inv_unidadesyprog_eclamc.asp
24 Centre for Arab Genomic Studies. Catalogue for transmission 
genetics in Arabs [Internet]. Dubai: CAGS [cited 2013 Jan 17]. 
Available from: http://www.cags.org.ae/ctga_search.html
25 World Health Organization. WHO Collaborating Centres global 
database [Internet]. Geneva: WHO [cited 2013 Jan 17]. Available 
from: http://apps.who.int/whocc and http://www.who.int/genomics
26  Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability 
of complex diseases. Nature 2009; 461:747–53. http://dx.doi.
org/10.1038/nature08494
27 Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome 
sequencing in health and disease. Ann Rev Med 2012; 63:35–61. 
http://dx.doi.org/10.1146/annurev-med-051010-162644
J R Coll Physicians Edinb 2013; 43:7–10
© 2013 RCPE
AH Bittles
invitatiOn tO submit papers
We would like to extend an invitation to all readers of The Journal of the Royal College 
of Physicians of Edinburgh to contribute original material, especially to the clinical 
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Fellows and Members.   All papers are subject to peer review and our turnaround 
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is a particularly good forum for research performed by junior doctors under consultant supervision. We would 
also consider clinical audits where the ‘loop has been closed’ and a demonstrable clinical benefit has resulted. 
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or e-mail editorial@rcpe.ac.uk. Thank you for your interest in the College’s journal.
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